Compugen Ltd. (CGEN)

NASDAQ: CGEN · Real-Time Price · USD
1.530
+0.010 (0.66%)
At close: Mar 28, 2025, 4:00 PM
1.540
+0.010 (0.65%)
After-hours: Mar 28, 2025, 6:54 PM EDT
0.66%
Market Cap 143.07M
Revenue (ttm) 27.86M
Net Income (ttm) -14.23M
Shares Out 93.51M
EPS (ttm) -0.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 136,324
Open 1.520
Previous Close 1.520
Day's Range 1.520 - 1.535
52-Week Range 1.350 - 2.660
Beta 2.98
Analysts Strong Buy
Price Target 4.00 (+161.44%)
Earnings Date Mar 4, 2025

About CGEN

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company’s pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/T... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 11, 2000
Employees 74
Stock Exchange NASDAQ
Ticker Symbol CGEN
Full Company Profile

Financial Performance

In 2024, Compugen's revenue was $27.86 million, a decrease of -16.72% compared to the previous year's $33.46 million. Losses were -$14.23 million, -24.12% less than in 2023.

Financial Statements

Analyst Forecast

According to one analyst, the rating for CGEN stock is "Strong Buy" and the 12-month stock price forecast is $4.0.

Price Target
$4.0
(161.44% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Compugen to Participate in Multiple Virtual Investor Conferences in April 2025

HOLON, Israel , March 26, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...

4 days ago - PRNewsWire

Compugen Ltd. (CGEN) Q4 2024 Earnings Call Transcript

Compugen Ltd. (NASDAQ:CGEN) Q4 2024 - Earnings Conference Call March 4, 2025 8:30 AM ET Company Participants Yvonne Naughton - VP, Head of IR and Corporate Communications Anat Cohen-Dayag - President...

26 days ago - Seeking Alpha

Compugen Reports Fourth Quarter and Full Year 2024 Results

Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibody On track to initiate a randomized adaptive platform trial of COM701 maintenanc...

26 days ago - PRNewsWire

Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference

HOLON, ISRAEL  , March 3, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...

27 days ago - PRNewsWire

Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology

Gene structure information identified by combining Compugen's AI/ML predictive computational discovery platform, Unigen™ with Ultima's UG 100™ sequencing platform to better understand tumor biology an...

4 weeks ago - PRNewsWire

Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025

HOLON, Israel , Feb. 18, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, ...

5 weeks ago - PRNewsWire

Compugen: Immuno-Oncology Innovator Poised For A Comeback

Compugen's innovative approach targets under-explored immune pathways like PVRIG and IL-18 binding protein, offering potential upside, despite current market skepticism. With $113.2 million in cash an...

5 weeks ago - Seeking Alpha

Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

HOLON, Israel , Feb. 4, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced th...

7 weeks ago - PRNewsWire

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors

New approach to harness cytokine biology to treat cancer patients advances to the clinic First patient dosed with potential first-in-class anti-IL-18 binding protein antibody, COM503, licensed to Gile...

2 months ago - PRNewsWire

Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies

Broad method of use patent protection for COM902, a potential best-in-class reduced Fc, clinical stage, anti-TIGIT antibody, in triple combination with any anti-PD-1 antibody and any anti-PVRIG antibo...

4 months ago - PRNewsWire

Compugen Ltd. (CGEN) Q3 2024 Earnings Call Transcript

Start Time: 08:30 January 1, 0000 9:30 AM ET Compugen Ltd. (NASDAQ:CGEN) Q3 2024 Earnings Call November 12, 2024, 08:30 AM ET Company Participants Anat Cohen-Dayag - President and CEO David Silberman...

4 months ago - Seeking Alpha

Compugen Reports Third Quarter 2024 Results

Clinical data presented at SITC 2024 demonstrated COM701 (anti-PVRIG) mediated anti-tumor activity with durable responses and good tolerability profile in tumors typically not responding to immunother...

4 months ago - PRNewsWire

Compugen to Participate in Stifel 2024 Healthcare Conference

HOLON, Israel , Nov. 11, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced t...

4 months ago - PRNewsWire

Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024

HOLON, ISRAEL , Nov. 5, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced th...

5 months ago - PRNewsWire

Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

HOLON, Israel , Oct. 29, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, ...

5 months ago - PRNewsWire

Compugen to Present New Clinical Data at SITC 2024

HOLON, Israel , Oct. 7, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, t...

6 months ago - PRNewsWire

Compugen to Present at Single Cell Genomics 2024 Conference

HOLON, Israel , Sept. 9, 2024 /PRNewswire/ -- Compugen Ltd.

7 months ago - PRNewsWire

Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

HOLON, Israel , Aug. 29, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...

7 months ago - PRNewsWire

Compugen Ltd. (CGEN) Q2 2024 Earnings Call Transcript

Compugen Ltd. (NASDAQ:CGEN) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Yvonne Naughton - Head of Investor Relations and Corporate Communications Anat Cohen-Dayag ...

8 months ago - Seeking Alpha

Compugen Reports Second Quarter 2024 Results

FDA clearance of COM503 IND in July 2024 triggered a $30 million milestone payment from Gilead  On track to present data from COM701 + COM902 + pembrolizumab, platinum resistant ovarian cancer study i...

8 months ago - PRNewsWire

Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harness cytokine biology for cancer th...

8 months ago - PRNewsWire

Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024

HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced t...

8 months ago - PRNewsWire

Compugen to Present at Upcoming Antibody Industrial Symposium

HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...

10 months ago - PRNewsWire

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in first-line nonsquamous non-small cell lung cancer Broadening th...

Other symbols: AZN
10 months ago - PRNewsWire

Compugen Ltd. (CGEN) Q1 2024 Earnings Call Transcript

Compugen Ltd. (NASDAQ:CGEN) Q1 2024 Earnings Call Transcript May 20, 2024 8:30 AM ET Company Participants Yvonne Naughton - Head of IR & Corporate Communications Anat Cohen-Dayag - President and CEO ...

11 months ago - Seeking Alpha